Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Technology
3.3. Snippet by Component
3.4. Snippet by Mode of Operation
3.5. Snippet by End-User
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Technological Advancements in Automated Compounding Devices
4.1.1.2. The Prevalence of Cancer
4.2. Restraints
4.2.1. The High Cost of ACD Systems
4.2.2. Opportunity
4.2.3. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index, By Product Type
7.2. Intravenous (IV) Compounding Systems *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Oral Liquid Compounding Systems
7.4. TPN (Total Parenteral Nutrition) Compounding Systems
7.5. Chemotherapy Compounding Systems
8. By Technology
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
8.1.2. Market Attractiveness Index, By Technology
8.2. Gravimetric Automated Compounding Devices *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Volumetric Automated Compounding Devices
8.4. Syringe-based Automated Compounding Devices
9. By Component
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
9.1.2. Market Attractiveness Index, By Component
9.2. Hardware *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Software
9.4. Services
10. By Mode of Operation
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Operation
10.1.2. Market Attractiveness Index, By Mode of Operation
10.2. Fully Automated Compounding Devices*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Semi-Automated Compounding Devices
11. By End-User
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.1.2. Market Attractiveness Index, By End-User
11.2. Hospitals*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Ambulatory Surgical Centers
11.4. Others
12. By Country
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.1.2. Market Attractiveness Index, By Country
12.2. North America
12.2.1. U.S.
12.2.2. Canada
12.2.3. Mexico
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis
14. Company Profiles
14.1. Grifols, S.A *
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Baxter International Inc
14.3. COMECER S.p.A.
14.4. ARxIUM
14.5. ICU Medical, Inc
14.6. Omnicell, Inc
14.7. EQUASHIELD
14.8. B. Braun Medical Inc
14.9. BECTON, DICKINSON, AND COMPANY
14.10. SMARTCOMPOUNDERS B.V. (*LIST NOT EXHAUSTIVE)
15. Appendix
15.1. About Us and Services
15.2. Contact Us